CGEN
Compugen Ltd.
Price Chart
Latest Quote
$2.01
+0.02 (+1.01%)
Current Price
| Previous Close | $1.99 |
| Open | $2.05 |
| Day High | $2.08 |
| Day Low | $1.97 |
| Volume | 503,223 |
Stock Information
| Shares Outstanding | 94.58M |
| Total Debt | $2.93M |
| Cash Equivalents | $134.95M |
| Revenue | $72.66M |
| Net Income | $34.85M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $190.12M |
| P/E Ratio | 5.29 |
| EPS (TTM) | $0.38 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $59.94M |
| Sales | $72.66M |
| Income | $34.85M |
| Book/sh | $1.01 |
| Cash/sh | $1.43 |
| Employees | 75 |
Financial Ratios
| Quick Ratio | 6.23 |
| Current Ratio | 6.23 |
| Debt/Eq | 3.08 |
Returns & Margins
| ROA | 14.69% |
| ROE | 45.72% |
| Gross Margin | 88.06% |
| Operating Margin | -414.38% |
| Profit Margin | 47.97% |
Ownership
| Insider Ownership | 2.08% |
| Institutional Ownership | 15.22% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.51 |
| PEG | 1.29 |
| P/S | 2.62 |
| P/B | 1.99 |
Analyst Data
| Recommendation | none |
| Target Price | $4.60 |
Technical Indicators
| SMA20 | $2.28 |
| SMA50 | $2.59 |
| SMA200 | $1.97 |
| RSI | 15.56 |
| ATR | 0.1221 |
| Shares Float | 92.42M |
| Short Float | 2.59% |
| Short Ratio | 4.55 |
| Volatility | 2.74 |
| Rel Volume | 1.05 |
Performance History
| Week | -1.47% |
| Month | -26.37% |
| Quarter | -4.74% |
| 6 Months | +34.90% |
| YTD | +29.68% |
| Year | +21.82% |
| 3 Years | +46.72% |
| 5 Years | -74.65% |
| 10 Years | -69.55% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.01 | 503,800 |
| 2026-06-17 | $1.99 | 275,700 |
| 2026-06-16 | $2.03 | 346,000 |
| 2026-06-15 | $2.02 | 288,500 |
| 2026-06-12 | $2.04 | 207,000 |
| 2026-06-11 | $2.04 | 359,200 |
| 2026-06-10 | $1.96 | 352,700 |
| 2026-06-09 | $2.02 | 462,800 |
| 2026-06-08 | $2.04 | 458,900 |
| 2026-06-05 | $2.10 | 242,400 |
| 2026-06-04 | $2.22 | 574,900 |
| 2026-06-03 | $2.19 | 807,800 |
| 2026-06-02 | $2.26 | 1,117,400 |
| 2026-06-01 | $2.46 | 738,200 |
| 2026-05-29 | $2.63 | 373,900 |
| 2026-05-28 | $2.78 | 545,600 |
| 2026-05-27 | $2.76 | 365,300 |
| 2026-05-26 | $2.65 | 417,800 |
| 2026-05-22 | $2.80 | 580,000 |
| 2026-05-21 | $2.61 | 541,200 |
| 2026-05-20 | $2.71 | 265,500 |
| 2026-05-19 | $2.73 | 956,000 |
About Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
đ° Latest News
Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions
Simply Wall St. âĸ 2026-06-18T04:39:36Z
Why The Narrative Around Compugen (NasdaqCM:CGEN) Is Shifting After Analyst Resets And New Views
Simply Wall St. âĸ 2026-06-03T20:10:45Z
Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
GuruFocus.com âĸ 2026-05-26T01:01:16ZCompugen Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-18T14:08:24Z
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-18T13:00:01Z
Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN)
InvestorsHub âĸ 2026-05-18T12:35:18Z
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-15T12:15:01Z
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-14T11:40:01Z
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T23:05:22Z
BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates
Zacks âĸ 2026-05-04T21:20:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $9,251,000 | $7,930,000 | $2,004,000 | $975,000 |
| Cost Of Revenue | $9,251,000 | $7,930,000 | $2,004,000 | $975,000 |
| Total Revenue | $72,764,000 | $27,864,000 | $33,459,000 | $7,500,000 |
| Operating Revenue | $72,764,000 | $27,864,000 | $33,459,000 | $7,500,000 |
| Expenses | ||||
| Total Expenses | $41,438,000 | $42,755,000 | $46,451,000 | $42,874,000 |
| Other Income Expense | $-309,000 | $-20,000 | $-2,000 | $328,000 |
| Net Non Operating Interest Income Expense | $4,380,000 | $5,202,000 | $3,210,000 | $1,410,000 |
| Total Other Finance Cost | $28,000 | $34,000 | $31,000 | $27,000 |
| Operating Expense | $32,187,000 | $34,825,000 | $44,447,000 | $41,899,000 |
| Selling And Marketing Expense | $539,000 | $576,000 | $244,000 | $932,000 |
| General And Administrative Expense | $8,891,000 | $9,439,000 | $9,731,000 | $10,319,000 |
| Interest Expense | - | - | - | $27,000 |
| Interest Expense Non Operating | - | - | - | $27,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $35,343,000 | $-14,231,000 | $-18,754,000 | $-33,694,000 |
| Net Interest Income | $4,380,000 | $5,202,000 | $3,210,000 | $1,410,000 |
| Interest Income | $4,408,000 | $5,236,000 | $3,241,000 | $1,437,000 |
| Normalized Income | $35,605,650 | $-14,215,600 | $-18,752,460 | $-33,946,560 |
| Net Income From Continuing And Discontinued Operation | $35,343,000 | $-14,231,000 | $-18,754,000 | $-33,694,000 |
| Total Operating Income As Reported | $31,326,000 | $-14,891,000 | $-12,992,000 | $-35,374,000 |
| Net Income Common Stockholders | $35,343,000 | $-14,231,000 | $-18,754,000 | $-33,694,000 |
| Net Income | $35,343,000 | $-14,231,000 | $-18,754,000 | $-33,694,000 |
| Net Income Including Noncontrolling Interests | $35,343,000 | $-14,231,000 | $-18,754,000 | $-33,694,000 |
| Net Income Continuous Operations | $35,343,000 | $-14,231,000 | $-18,754,000 | $-33,694,000 |
| Pretax Income | $35,397,000 | $-9,709,000 | $-9,784,000 | $-33,636,000 |
| Special Income Charges | $1,000 | $0 | $-7,000 | $-12,000 |
| Interest Income Non Operating | $4,408,000 | $5,236,000 | $3,241,000 | $1,437,000 |
| Operating Income | $31,326,000 | $-14,891,000 | $-12,992,000 | $-35,374,000 |
| Gross Profit | $63,513,000 | $19,934,000 | $31,455,000 | $6,525,000 |
| Per Share | ||||
| Diluted EPS | $0.38 | $-0.16 | $-0.21 | $-0.39 |
| Basic EPS | $0.38 | $-0.16 | $-0.21 | $-0.39 |
| Other | ||||
| Tax Effect Of Unusual Items | $-46,350 | $-4,600 | $-460 | $75,440 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $32,110,000 | $-14,385,000 | $-12,514,000 | $-35,220,000 |
| Total Unusual Items | $-309,000 | $-20,000 | $-2,000 | $328,000 |
| Total Unusual Items Excluding Goodwill | $-309,000 | $-20,000 | $-2,000 | $328,000 |
| Reconciled Depreciation | $475,000 | $486,000 | $476,000 | $482,000 |
| EBITDA (Bullshit earnings) | $31,801,000 | $-14,405,000 | $-12,516,000 | $-34,892,000 |
| EBIT | $31,326,000 | $-14,891,000 | $-12,992,000 | $-35,374,000 |
| Diluted Average Shares | $93,815,083 | $89,528,031 | $87,633,298 | $86,555,628 |
| Basic Average Shares | $93,425,341 | $89,528,031 | $87,633,298 | $86,555,628 |
| Diluted NI Availto Com Stockholders | $35,343,000 | $-14,231,000 | $-18,754,000 | $-33,694,000 |
| Tax Provision | $54,000 | $4,522,000 | $8,970,000 | $58,000 |
| Gain On Sale Of Ppe | $1,000 | $0 | $-7,000 | $-12,000 |
| Gain On Sale Of Security | $-310,000 | $-20,000 | $5,000 | $340,000 |
| Research And Development | $22,757,000 | $24,810,000 | $34,472,000 | $30,648,000 |
| Selling General And Administration | $9,430,000 | $10,015,000 | $9,975,000 | $11,251,000 |
| Other Gand A | $8,891,000 | $9,439,000 | $9,731,000 | $10,319,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $102,731,000 | $54,914,000 | $65,559,000 | $77,680,000 |
| Total Assets | $156,570,000 | $114,995,000 | $121,334,000 | $94,176,000 |
| Total Non Current Assets | $8,548,000 | $8,998,000 | $6,755,000 | $8,051,000 |
| Other Non Current Assets | $410,000 | $343,000 | - | - |
| Non Current Prepaid Assets | $1,293,000 | $1,888,000 | $1,233,000 | $1,899,000 |
| Current Assets | $148,022,000 | $105,997,000 | $114,579,000 | $86,125,000 |
| Prepaid Assets | $2,088,000 | $2,473,000 | $2,211,000 | $2,100,000 |
| Receivables | $294,000 | $269,000 | $61,318,000 | $317,000 |
| Other Receivables | $294,000 | $269,000 | $318,000 | $317,000 |
| Cash Cash Equivalents And Short Term Investments | $145,640,000 | $103,255,000 | $50,685,000 | $83,346,000 |
| Cash And Cash Equivalents | $90,597,000 | $18,229,000 | $13,890,000 | $11,059,000 |
| Restricted Cash | - | $0 | $365,000 | $362,000 |
| Accounts Receivable | - | $0 | $61,000,000 | $0 |
| Debt | ||||
| Total Debt | $2,960,000 | $2,912,000 | $1,351,000 | $1,925,000 |
| Long Term Debt And Capital Lease Obligation | $2,439,000 | $2,464,000 | $719,000 | $1,312,000 |
| Current Debt And Capital Lease Obligation | $521,000 | $448,000 | $632,000 | $613,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $53,839,000 | $60,081,000 | $55,775,000 | $16,496,000 |
| Total Non Current Liabilities Net Minority Interest | $31,269,000 | $39,921,000 | $29,509,000 | $4,577,000 |
| Non Current Deferred Liabilities | $24,943,000 | $34,045,000 | $25,392,000 | $0 |
| Current Liabilities | $22,570,000 | $20,160,000 | $26,266,000 | $11,919,000 |
| Current Deferred Liabilities | $10,970,000 | $9,632,000 | $11,149,000 | $325,000 |
| Payables And Accrued Expenses | $8,029,000 | $7,006,000 | $11,360,000 | $8,169,000 |
| Payables | $2,353,000 | $1,838,000 | $3,502,000 | $1,773,000 |
| Accounts Payable | $2,353,000 | $1,838,000 | $3,502,000 | $1,773,000 |
| Equity | ||||
| Common Stock Equity | $102,731,000 | $54,914,000 | $65,559,000 | $77,680,000 |
| Total Equity Gross Minority Interest | $102,731,000 | $54,914,000 | $65,559,000 | $77,680,000 |
| Stockholders Equity | $102,731,000 | $54,914,000 | $65,559,000 | $77,680,000 |
| Gains Losses Not Affecting Retained Earnings | $8,000 | $11,000 | $2,000 | $0 |
| Other Equity Adjustments | $8,000 | $11,000 | $2,000 | - |
| Retained Earnings | $-453,415,000 | $-488,758,000 | $-474,527,000 | $-455,773,000 |
| Other | ||||
| Ordinary Shares Number | $94,553,191 | $89,541,246 | $89,237,465 | $86,624,643 |
| Share Issued | $94,553,191 | $89,541,246 | $89,237,465 | $86,624,643 |
| Tangible Book Value | $102,731,000 | $54,914,000 | $65,559,000 | $77,680,000 |
| Invested Capital | $102,731,000 | $54,914,000 | $65,559,000 | $77,680,000 |
| Working Capital | $125,452,000 | $85,837,000 | $88,313,000 | $74,206,000 |
| Capital Lease Obligations | $2,960,000 | $2,912,000 | $1,351,000 | $1,925,000 |
| Total Capitalization | $102,731,000 | $54,914,000 | $65,559,000 | $77,680,000 |
| Additional Paid In Capital | $555,876,000 | $543,413,000 | $539,837,000 | $533,213,000 |
| Capital Stock | $262,000 | $248,000 | $247,000 | $240,000 |
| Common Stock | $262,000 | $248,000 | $247,000 | $240,000 |
| Employee Benefits | $3,887,000 | $3,412,000 | $3,398,000 | $3,265,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $3,887,000 | $3,412,000 | $3,398,000 | $3,265,000 |
| Non Current Deferred Revenue | $24,943,000 | $34,045,000 | $25,392,000 | $0 |
| Long Term Capital Lease Obligation | $2,439,000 | $2,464,000 | $719,000 | $1,312,000 |
| Current Deferred Revenue | $10,970,000 | $9,632,000 | $11,149,000 | $0 |
| Current Capital Lease Obligation | $521,000 | $448,000 | $632,000 | $613,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,050,000 | $3,074,000 | $3,125,000 | $2,812,000 |
| Current Accrued Expenses | $5,676,000 | $5,168,000 | $7,858,000 | $6,396,000 |
| Defined Pension Benefit | $3,643,000 | $3,072,000 | $2,977,000 | $2,794,000 |
| Net PPE | $3,202,000 | $3,695,000 | $2,545,000 | $3,358,000 |
| Accumulated Depreciation | $-6,219,000 | $-5,748,000 | $-5,356,000 | $-6,230,000 |
| Gross PPE | $9,421,000 | $9,443,000 | $7,901,000 | $9,588,000 |
| Leases | $2,319,000 | $2,314,000 | $2,314,000 | $2,314,000 |
| Other Properties | $2,521,000 | $2,843,000 | $1,329,000 | $1,826,000 |
| Machinery Furniture Equipment | $4,581,000 | $4,286,000 | $4,258,000 | $5,448,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $55,043,000 | $85,026,000 | $36,795,000 | $72,287,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $31,328,000 | $49,486,000 | $-36,058,000 | $-34,600,000 |
| Operating Activities | ||||
| Operating Cash Flow | $31,634,000 | $49,604,000 | $-35,886,000 | $-34,113,000 |
| Cash Flow From Continuing Operating Activities | $31,634,000 | $49,604,000 | $-35,886,000 | $-34,113,000 |
| Operating Gains Losses | $-232,000 | $-149,000 | $-172,000 | $324,000 |
| Investing Activities | ||||
| Capital Expenditure | $-306,000 | $-118,000 | $-172,000 | $-487,000 |
| Investing Cash Flow | $29,995,000 | $-46,252,000 | $35,510,000 | $37,060,000 |
| Cash Flow From Continuing Investing Activities | $29,995,000 | $-46,252,000 | $35,510,000 | $37,060,000 |
| Net Other Investing Changes | $-16,000 | $-330,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,535,000 | $544,000 | $3,081,000 | $0 |
| Financing Cash Flow | $10,604,000 | $554,000 | $3,081,000 | $353,000 |
| Cash Flow From Continuing Financing Activities | $10,604,000 | $554,000 | $3,081,000 | $353,000 |
| Net Other Financing Charges | $-4,000 | - | - | - |
| Net Common Stock Issuance | $10,535,000 | $544,000 | $3,081,000 | $0 |
| Common Stock Issuance | $10,535,000 | $544,000 | $3,081,000 | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $55,000 | $13,517,000 | $12,000 | - |
| End Cash Position | $90,597,000 | $18,229,000 | $14,255,000 | $11,421,000 |
| Beginning Cash Position | $18,229,000 | $14,255,000 | $11,421,000 | $8,514,000 |
| Effect Of Exchange Rate Changes | $135,000 | $68,000 | $129,000 | $-393,000 |
| Changes In Cash | $72,233,000 | $3,906,000 | $2,705,000 | $3,300,000 |
| Proceeds From Stock Option Exercised | $73,000 | $10,000 | $0 | $353,000 |
| Net Investment Purchase And Sale | $30,316,000 | $-45,805,000 | $35,682,000 | $37,545,000 |
| Sale Of Investment | $126,370,000 | $113,947,000 | $89,387,000 | $114,445,000 |
| Purchase Of Investment | $-96,054,000 | $-159,752,000 | $-53,705,000 | $-76,900,000 |
| Net PPE Purchase And Sale | $-305,000 | $-117,000 | $-172,000 | $-485,000 |
| Sale Of PPE | $1,000 | $1,000 | $0 | $2,000 |
| Purchase Of PPE | $-306,000 | $-118,000 | $-172,000 | $-487,000 |
| Change In Working Capital | $-5,348,000 | $62,050,000 | $-20,706,000 | $-5,553,000 |
| Change In Other Working Capital | $-7,788,000 | $7,085,000 | $36,529,000 | $-6,019,000 |
| Change In Other Current Liabilities | $-109,000 | $-503,000 | $-645,000 | $-1,062,000 |
| Change In Other Current Assets | $479,000 | $550,000 | $568,000 | $658,000 |
| Change In Payables And Accrued Expense | $1,017,000 | $-4,359,000 | $3,196,000 | $-1,601,000 |
| Change In Accrued Expense | $500,000 | $-2,690,000 | $1,462,000 | - |
| Change In Payable | $517,000 | $-1,669,000 | $1,734,000 | $-1,601,000 |
| Change In Account Payable | $517,000 | $-1,669,000 | $1,734,000 | $-1,601,000 |
| Change In Prepaid Assets | $595,000 | $-655,000 | $666,000 | $12,000 |
| Change In Receivables | $458,000 | $59,932,000 | $-61,020,000 | $2,459,000 |
| Changes In Account Receivables | $0 | $61,000,000 | $-61,000,000 | $0 |
| Other Non Cash Items | $-485,000 | $-1,575,000 | $-280,000 | - |
| Stock Based Compensation | $1,881,000 | $3,023,000 | $3,550,000 | $4,328,000 |
| Depreciation Amortization Depletion | $475,000 | $486,000 | $476,000 | $482,000 |
| Depreciation And Amortization | $475,000 | $486,000 | $476,000 | $482,000 |
| Depreciation | $475,000 | $486,000 | $476,000 | $482,000 |
| Pension And Employee Benefit Expense | $-96,000 | $-81,000 | $-50,000 | $-81,000 |
| Net Foreign Currency Exchange Gain Loss | $-135,000 | $-68,000 | $-129,000 | $393,000 |
| Gain Loss On Sale Of PPE | $-1,000 | $0 | $7,000 | $12,000 |
| Net Income From Continuing Operations | $35,343,000 | $-14,231,000 | $-18,754,000 | $-33,694,000 |
| Interest Paid Supplemental Data | - | - | $3,052,000 | $852,000 |
Fetched: 2026-06-19